source
- Western pharma firms lobby Trump administration to preserve China partnership opportunitiesWestern pharmaceutical companies are urging the Trump administration to permit continued collaborations with Chinese firms on promising drug candidates, despite a 2025 law that limits U.S. investme…
- Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorderWith a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could supp…